Bernard Escudier Selected Research

Everolimus

1/2022	Activity of Systemic Treatments After Cabozantinib Failure in Advanced Metastatic Renal Cell Carcinoma.
10/2021	Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales).
9/2021	Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
8/2021	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma.
1/2020	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long-term follow-up of the randomized, open-label, phase 3 CheckMate 025 trial.
1/2020	Outcomes based on age in the phase III METEOR trial of cabozantinib versus everolimus in patients with advanced renal cell carcinoma.
10/2019	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.
10/2018	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.
10/2018	Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial.
1/2018	Erratum to "CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma" [Eur Urol 2017;72:962-71].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bernard Escudier Research Topics

Disease

230	Renal Cell Carcinoma (Grawitz Tumor) 05/2022 - 07/2003
106	Neoplasms (Cancer) 02/2022 - 03/2002
35	Kidney Neoplasms (Kidney Cancer) 01/2021 - 04/2002
21	Fatigue 01/2020 - 01/2007
15	Disease Progression 01/2021 - 01/2007
15	Neoplasm Metastasis (Metastasis) 10/2018 - 01/2006
13	Hypertension (High Blood Pressure) 01/2022 - 01/2007
11	Melanoma (Melanoma, Malignant) 01/2020 - 03/2002
8	Hypoxia (Hypoxemia) 10/2016 - 01/2007
7	Prostatic Neoplasms (Prostate Cancer) 05/2022 - 03/2003
7	Diarrhea 10/2018 - 01/2007
6	Exanthema (Rash) 10/2016 - 01/2007
6	Carcinoma (Carcinomatosis) 11/2015 - 05/2007
4	Stomatitis 01/2020 - 08/2008
4	Pain (Aches) 11/2018 - 03/2002
4	Nausea 10/2018 - 03/2007
4	Proteinuria 12/2015 - 01/2011
3	Dyspnea (Shortness of Breath) 10/2018 - 06/2007
3	Hyperglycemia 10/2016 - 03/2014
3	Pneumonia (Pneumonitis) 03/2014 - 08/2008
3	Clear-cell metastatic renal cell carcinoma 03/2014 - 12/2012
3	Asthenia 03/2013 - 12/2007
3	Alopecia (Baldness) 12/2011 - 03/2007
2	Pruritus (Itching) 01/2020 - 02/2009
2	Brain Neoplasms (Brain Tumor) 10/2019 - 02/2014
2	Body Weight (Weight, Body) 04/2018 - 11/2015
2	Stomach Neoplasms (Stomach Cancer) 10/2017 - 10/2014
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 01/2017 - 03/2011
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2017 - 10/2010
2	Anemia 12/2016 - 11/2015
2	Posterior Leukoencephalopathy Syndrome 10/2016 - 02/2014
2	Hypercholesterolemia 10/2016 - 03/2014
2	Edema (Dropsy) 12/2015 - 04/2012
2	Renal Insufficiency (Renal Failure) 09/2013 - 05/2007
2	Hand-Foot Syndrome 05/2013 - 07/2008
2	Cough 04/2012 - 06/2007
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2012 - 08/2009
2	Keratoacanthoma 01/2012 - 08/2009

Drug/Important Bio-Agent (IBA)

63	Sunitinib (Sutent)FDA Link 02/2022 - 01/2008
44	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2022 - 06/2004
37	Sorafenib (BAY 43-9006)FDA Link 01/2022 - 05/2006
34	Everolimus FDA Link 01/2022 - 08/2008
30	Bevacizumab (Avastin)FDA Link 02/2022 - 12/2007
27	NivolumabIBA 01/2022 - 11/2015
24	Tyrosine Kinase InhibitorsIBA 01/2021 - 01/2006
21	Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA 08/2020 - 08/2005
18	Biomarkers (Surrogate Marker)IBA 09/2021 - 06/2004
17	Immune Checkpoint InhibitorsIBA 05/2022 - 11/2015
17	cabozantinibIBA 01/2022 - 11/2015
15	Axitinib (AG 013736)IBA 06/2020 - 01/2011
13	CytokinesIBA 03/2020 - 03/2002
12	IpilimumabIBA 01/2022 - 04/2018
12	Interleukin-2 (IL2)IBA 12/2017 - 03/2002
10	TOR Serine-Threonine KinasesIBA 01/2019 - 08/2008
9	Pharmaceutical PreparationsIBA 01/2021 - 03/2002
9	Biological ProductsIBA 11/2018 - 08/2003
8	atezolizumabIBA 02/2022 - 01/2018
8	Peptides (Polypeptides)IBA 01/2020 - 02/2004
8	Interferon-alpha (Interferon Alfa)IBA 03/2017 - 01/2006
8	InterferonsIBA 08/2016 - 04/2002
8	temsirolimus FDA Link 10/2015 - 09/2008
7	pazopanib FDA Link 12/2021 - 01/2011
7	Proteins (Proteins, Gene)FDA Link 10/2016 - 10/2002
5	LigandsIBA 02/2022 - 02/2005
5	B7-H1 AntigenIBA 01/2022 - 10/2016
5	Phosphotransferases (Kinase)IBA 01/2022 - 07/2005
5	Angiogenesis InhibitorsIBA 12/2021 - 12/2005
5	AntigensIBA 01/2020 - 03/2002
5	Monoclonal AntibodiesIBA 08/2017 - 06/2014
4	MTOR InhibitorsIBA 10/2015 - 08/2010
4	Interferon alpha-2 (Roferon-A)FDA Link 05/2010 - 12/2007
3	Messenger RNA (mRNA)IBA 06/2020 - 03/2002
3	4- amino- 5- fluoro- 3- (5- (4- methylpiperazin- 1- yl)- 1H- benzimidazol- 2- yl)quinolin- 2(1H)- oneIBA 06/2014 - 03/2013
3	T-Cell Antigen Receptors (T-Cell Receptor)IBA 04/2008 - 10/2002
3	HLA-A2 Antigen (HLA A2 Antigen)IBA 03/2005 - 02/2004
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 02/2022 - 12/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 01/2018
2	Amylases FDA Link 10/2019 - 12/2015
2	CrizotinibIBA 11/2018 - 12/2017
2	tivozanibIBA 11/2018 - 08/2014
2	Tyrosine (L-Tyrosine)FDA Link 10/2018 - 10/2002
2	Imatinib Mesylate (Gleevec)FDA Link 01/2017 - 10/2010
2	Cisplatin (Platino)FDA LinkGeneric 01/2017 - 05/2007
2	InterleukinsIBA 08/2016 - 06/2007
2	AndrogensIBA 01/2016 - 09/2015
2	Interleukin-6 (Interleukin 6)IBA 11/2015 - 06/2004
2	Epidermal Growth Factor (EGF)IBA 07/2014 - 12/2012
2	Fibroblast Growth Factors (Fibroblast Growth Factor)IBA 06/2014 - 03/2013
2	Carbonic Anhydrase IXIBA 12/2012 - 10/2010
2	Gemcitabine FDA Link 05/2012 - 05/2007
2	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2012 - 11/2009
2	PlatinumIBA 05/2012 - 05/2007

Therapy/Procedure

120	Therapeutics 12/2021 - 03/2002
26	Nephrectomy 01/2022 - 12/2005
11	Immunotherapy 03/2020 - 03/2002
11	Drug Therapy (Chemotherapy) 01/2017 - 07/2003
5	Radiotherapy 11/2018 - 04/2014
5	Castration 01/2016 - 05/2009
3	Injections 10/2009 - 03/2002
2	Molecular Targeted Therapy 06/2016 - 02/2014